150 related articles for article (PubMed ID: 38044852)
1. Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.
Zhu W; Fang X; Zheng J; Ke Y; He Q; Cui T; Chen B; Tian L
Ren Fail; 2023; 45(2):2285873. PubMed ID: 38044852
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients.
Tosukhowong T; Eiam-Ong S; Thamutok K; Wittayalertpanya S; Na Ayudhya DP
Perit Dial Int; 2001; 21(6):587-94. PubMed ID: 11783768
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ceftazidime in CAPD-related peritonitis.
Booranalertpaisarn V; Eiam-Ong S; Wittayalertpanya S; Kanjanabutr T; Na Ayudhya DP
Perit Dial Int; 2003; 23(6):574-9. PubMed ID: 14703199
[TBL] [Abstract][Full Text] [Related]
4. Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients.
Peerapornratana S; Chariyavilaskul P; Kanjanabuch T; Praditpornsilpa K; Eiam-Ong S; Katavetin P
Perit Dial Int; 2017; 37(2):218-224. PubMed ID: 27738089
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis.
Triyawatanyu P; Chariyavilaskul P; Phaisal W; Peerapornratana S; Kanjanabuch T; Praditpornsilpa K; Katavetin P
Perit Dial Int; 2020 Mar; 40(2):179-184. PubMed ID: 32063189
[TBL] [Abstract][Full Text] [Related]
6. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function.
Lui SL; Cheng SW; Ng F; Ng SY; Wan KM; Yip T; Tse KC; Lam MF; Lai KN; Lo WK
Kidney Int; 2005 Nov; 68(5):2375-80. PubMed ID: 16221243
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial.
Kitrungphaiboon T; Puapatanakul P; Chuengsaman P; Tiskajornsiri K; Halue G; Siribamrungwong M; Matayart S; Chongthanakorn K; Poonvivatchaikarn U; Boonyakrai C; Somboonsilp W; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Johnson DW; Kanjanabuch T
Am J Kidney Dis; 2019 Nov; 74(5):601-609. PubMed ID: 31331757
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
Grabe DW; Bailie GR; Eisele G; Frye RF
Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
[TBL] [Abstract][Full Text] [Related]
9. Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.
Sisterhen LL; Stowe CD; Farrar HC; Blaszak CK; Blaszak RT
Am J Kidney Dis; 2006 Mar; 47(3):503-8. PubMed ID: 16490630
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients.
Elwell RJ; Manley HJ; Frye RF; Bailie GR
Int J Artif Organs; 2005 Aug; 28(8):808-16. PubMed ID: 16211531
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.
Roberts DM; Ranganathan D; Wallis SC; Varghese JM; Kark A; Lipman J; Roberts JA
Perit Dial Int; 2016; 36(4):415-20. PubMed ID: 26764340
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of peritoneal dialysis-associated peritonitis with cefazolin and ceftazidime in children.
Rusthoven E; Monnens LA; Schröder CH
Perit Dial Int; 2001; 21(4):386-9. PubMed ID: 11587402
[TBL] [Abstract][Full Text] [Related]
14. Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.
Cardone KE; Grabe DW; Zasowski EJ; Lodise TP
Antimicrob Agents Chemother; 2014; 58(1):19-26. PubMed ID: 24126585
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilic peritonitis in a patient with continuous ambulatory peritoneal dialysis (CAPD).
Oh SY; Kim H; Kang JM; Lim SH; Park HD; Jung SS; Lee KB
Korean J Intern Med; 2004 Jun; 19(2):121-3. PubMed ID: 15366644
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.
Manley HJ; Elwell RJ; Bailie GR; Welch CL
Ann Pharmacother; 2004 Dec; 38(12):2035-40. PubMed ID: 15536141
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Low CL; Gopalakrishna K; Lye WC
J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of culture-directed antibiotics for the treatment of peritonitis in automated peritoneal dialysis: A systematic narrative review.
Ling CW; Sud K; Van C; Zaidi STR; Patel RP; Peterson GM; Castelino RL
Perit Dial Int; 2021 May; 41(3):261-272. PubMed ID: 33559525
[TBL] [Abstract][Full Text] [Related]
19. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS).
Schaefer F; Klaus G; Müller-Wiefel DE; Mehls O
J Am Soc Nephrol; 1999 Jan; 10(1):136-45. PubMed ID: 9890319
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].
Ryckelynck JP; Vergnaud M; Hurault de Ligny B; Allouche G; Malbruny B; Morel C
Pathol Biol (Paris); 1986 May; 34(5):328-31. PubMed ID: 3534700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
